Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Filip Ionescu, Shrinjaya B Thapa, Parth C Patel, Dimitrios Drekolias, Ariosto Siqueira Silva, Praneeth R Sudalagunta, Phaedra Agius, Brandon Blue, Doris K. Hansen, Omar Castaneda, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise Freeman, Frederick Locke, Taiga Nishihori, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Ariel Grajales-Cruz

Blood (2024) 144 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2024-210069

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Blood (2024) 144 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2024-211739

Published: 2024

Journal Articles

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Mark B. Meads, Xiaohong Zhao, David R. Noyes, Alexandra Achille, Praneeth Reddy Sudalagunta, Chaomei H. Zhang, Sonila Toska, Jongphil Kim, Samer Sansil, Sean J. Yoder, Ariel Grajales-Cruz, Brandon Blue, Ciara Louise Freeman, Melissa Alsina, Ariosto Siqueira Silva, Xiaofei Song, Rachid Baz, Kenneth H. Shain

Blood (2024) 144 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2024-210232

Published: 2024

Journal Articles

Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Fnu Amisha, Ziad Abuhelwa, Wenyi Fan, Doris K. Hansen, Omar Castaneda, Ciara Louise Freeman, Hien Liu, Frederick Locke, Taiga Nishihori, Ariel Grajales-Cruz, Brandon Blue, Kenneth H. Shain, Melissa Alsina, Rachid Baz

Blood (2024) 144 (Supplement 1): 2004.

https://doi.org/10.1182/blood-2024-211822

Published: 2024

Journal Articles

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Doris K. Hansen, Ariel F. Grajales-Cruz, Brandon Blue, Omar Castaneda, Hien Liu, Ciara Louise Freeman, Taiga Nishihori, Frederick Locke, Kenneth H. Shain, Rachid Baz, Melissa Alsina

Blood (2024) 144 (Supplement 1): 4692.

https://doi.org/10.1182/blood-2024-204270

Published: 2024

Journal Articles

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2024-204232

Published: 2024

Journal Articles

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

Jerald Noble, Xiaofei Song, Meghan Menges, Julieta Abraham-Miranda, Salvatore Corallo, Gabriel De Avila, Omar Puglianini, Hien Liu, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Rachid Baz, Brandon Blue, Ariel Grajales-Cruz, Doris K. Hansen, Reginald Atkins, Frederick L. Locke, Ciara Louise Freeman

Blood (2024) 144 (Supplement 1): 7173.

https://doi.org/10.1182/blood-2024-208709

Published: 2024

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Blood (2024) 144 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2024-204276

Published: 2024

Journal Articles

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Ciara Louise L. Freeman, Xiaohong Zhao, Mark B Meads, Jerald Noble, Raghunandan Reddy Alugubelli, Rafael Renatino-Canevarolo, Oliver Hampton, Praneeth Reddy Sudalagunta, Ariosto Siqueira Silva, Rachid Baz, Melissa Alsina, Doris K. Hansen, Xiaofei Song, Kenneth H. Shain

Blood (2023) 142 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2023-191013

Published: 2023

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

Ciara Louise L. Freeman, Julieta Abraham Miranda, Meghan Menges, Jerald Noble, Hien Liu, Salvatore Corallo, Albert J Ribickas, Constanza Savid-Frontera, Gabriel De Avila, Omar Castaneda, Jose L. Ochoa-Bayona, Rachid Baz, Doris K. Hansen, Melissa Alsina, Kenneth H. Shain, Taiga Nishihori, Reginald Atkins, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2023-187539

Published: 2023

Journal Articles

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Blood (2023) 142 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2023-185930

Published: 2023

Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Blood (2023) 142 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2023-173812

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Ariel F. Grajales-Cruz, Omar Castaneda, Doris K. Hansen, Mariola A Vazquez-Martinez, Brandon Blue, Sushmita Khadka, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise L. Freeman, Frederick L. Locke, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina

Blood (2023) 142 (Supplement 1): 3351.

https://doi.org/10.1182/blood-2023-184928

Published: 2023

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only